BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-716@pharmaconomics
DTSTAMP:20260707T045556Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:SGMO PDUFA — isaralgagene civaparvovec
DESCRIPTION:The FDA's approval decision on isaralgagene civaparvovec for Fabry disease is due Jun 30\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/exhibit-991033026.htm\n\nTrack it: https://www.pharmaconomics.com/e/716
URL:https://www.pharmaconomics.com/e/716
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SGMO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR